1964
DOI: 10.1042/bj0910064
|View full text |Cite
|
Sign up to set email alerts
|

Transformation of porphobilinogen into porphyrins by preparations from human erythrocytes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

4
19
0

Year Published

1974
1974
1989
1989

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 58 publications
(23 citation statements)
references
References 21 publications
4
19
0
Order By: Relevance
“…Hemolysates from the patients with PCT demonstrated decreased URODECARB activity with either substrate and, as with the controls, there was no difference in the activity of the erythrocyte enzyme in decarboxylating uroporphyrinogen I or III.-The equivalent decarboxylation of either substrate is in agreement with the findings of Romeo and Levin for mouse spleen URODECARB (36) and our own finding for porcine hepatic URODECARB (25). Although older data suggest that the rate of decarboxylation is higher with the type III isomer (37)(38)(39), Inherited Enzymatic Defect in Porphyria Cutanea Tarda 1095 the current studies support the validity of assaying human hepatic URODECARB with uroporphyrinogen I as the substrate. If URODECARB deficiency is the underlying defect in heme biosynthesis in PCT, then the question arises as to why no heme deficiency is observed.…”
Section: Introductionsupporting
confidence: 82%
“…Hemolysates from the patients with PCT demonstrated decreased URODECARB activity with either substrate and, as with the controls, there was no difference in the activity of the erythrocyte enzyme in decarboxylating uroporphyrinogen I or III.-The equivalent decarboxylation of either substrate is in agreement with the findings of Romeo and Levin for mouse spleen URODECARB (36) and our own finding for porcine hepatic URODECARB (25). Although older data suggest that the rate of decarboxylation is higher with the type III isomer (37)(38)(39), Inherited Enzymatic Defect in Porphyria Cutanea Tarda 1095 the current studies support the validity of assaying human hepatic URODECARB with uroporphyrinogen I as the substrate. If URODECARB deficiency is the underlying defect in heme biosynthesis in PCT, then the question arises as to why no heme deficiency is observed.…”
Section: Introductionsupporting
confidence: 82%
“…URODECARB has been reported to catalyze the decarboxylation of UROGEN III at a faster rate than UROGEN I (12,23). However, Romeo and Levin found that URODECARB extracted from mouse spleen decarboxylates both isomers at the same rate (11).…”
Section: Discussionmentioning
confidence: 99%
“…Reports about heat stability and effect of different sodium salt concentrations on the stepwise decarboxylation [l, 4,8,9,22] and the rates of decarboxylation towards different substrates [4, 9, 20, 21, 231 suggest the presence of more than one active centre. Evidence from studies of partially purified enzyme [8, 21, 241 and of uroporphyrinogen decarboxylase purified to homogeneity [l, 4, 51 indicated that the decarboxylation of uroporphyrinogen to coproporphyrinogen is catalyzed by a single protein.…”
Section: Discussionmentioning
confidence: 99%